Navigation Links
Short-Term Drug Combo May Help Prevent Colon Cancer
Date:3/29/2010

Lab research finds only precancerous tissue affected, but more study needed

MONDAY, March 29 (HealthDay News) -- A two-drug combination that kills precancerous colon polyps without harming normal tissue offers a potential new way to prevent colon cancer, researchers say.

The combination of vitamin A acetate (RAc) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was effective in mice and in human colon cancer tissue in the lab, according to the results of a study published online March 28 in the journal Nature.

The treatment appears to solve a problem with current chemopreventive drugs, which is that they must be taken continuously and long term to be effective, thus exposing patients to possible side effects, said study senior author Xiangwei Wu, an associate professor in the head and neck surgery department at the University of Texas M.D. Anderson Cancer Center.

"This combination can be given short term and periodically to provide a long-term effect, which would be a new approach to chemoprevention," Wu said in a university news release.

However, further research is needed before this combination treatment can be considered for human clinical trials, Wu said.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about colon polyps.



-- Robert Preidt



SOURCE: University of Texas M.D. Anderson Cancer Center, news release, March 28, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Los Angeles Jewish Home Adds Short-Term Rehabilitative Care to Family of Services
2. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
3. Short-term radiation therapy successful on breast cancer
4. SNM calls Congress passage of fix for sustainable growth rate a short-term solution
5. Drug Combo Blocks HIV Infection in Mice
6. Combo PET-CT Scans Can Spot Hidden Cancers
7. Blood Thinner Combos Risky for Heart Attack Patients
8. OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
9. Preventive Mastectomy May Not Lower Risks
10. Targeting cell pathway may prevent relapse of leukemia
11. Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)...  Eli Lilly and Company (NYSE: ... Phase 3 MONARCH 2 study showed that abemaciclib, ... combination with fulvestrant, significantly improved progression-free survival (PFS) ... with hormone-receptor-positive (HR+), human epidermal growth factor receptor ... or progressed after endocrine therapy (median PFS, 16.4 ...
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology: